Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01147809 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
NCT01147809 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 130 participants.
The verdict
NCT01147809, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
Study Summary
The present study is a randomized, blinded, placebo-controlled, two-Phase, sequential cohort, dose finding study to assess the safety and efficacy of eltrombopag in patients with solid tumors receiving gemcitabine monotherapy or the combination of gemcitabine plus carboplatin or cisplatin. Phase I of the study will examine safety and tolerability of various doses of eltrombopag to identify a dose and schedule of eltrombopag. Phase II will confirm that the chosen dose and schedule of eltrombopag from Phase I can deliver clinically meaningful benefit(s) to thrombocytopenic patients by improving platelet numbers.
Interventions
- OTHER Placebo
- DRUG Eltrombopag olamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2010-06 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01147809
The ClinicalTrials.gov registry entry for NCT01147809 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01147809 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01147809 about?
NCT01147809 is a clinical study titled "Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag". The present study is a randomized, blinded, placebo-controlled, two-Phase, sequential cohort, dose finding study to assess the safety and efficacy of eltrombopag in patients with solid tumors receiving gemcitabine monotherapy or the combination of gemcitabine plus carboplatin or cisplatin. Phase I o...
What is the current status of trial NCT01147809?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2010-06. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01147809?
The interventions under investigation include: Placebo (OTHER), Eltrombopag olamine (DRUG).
Who is sponsoring clinical trial NCT01147809?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.